Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Study to Evaluate the Pharmacodynamic Effects of Single-Dose Co-Administration of LX4211 With Januvia® in Type 2 Diabetics

This study has been completed.
Information provided by (Responsible Party):
Lexicon Pharmaceuticals Identifier:
First received: September 23, 2011
Last updated: January 26, 2012
Last verified: January 2012
This study is intended to evaluate the pharmacodynamics, safety, and tolerability of LX4211 when administered concurrently with sitagliptin (Januvia®) in patients with Type 2 Diabetes Mellitus.

Condition Intervention Phase
Type 2 Diabetes Mellitus
Drug: LX4211
Drug: Januvia®
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1, Open-label, 3-period, 3-treatment, Single Dose Crossover Study to Evaluate the Pharmacodynamic Effects of LX4211 When Administered Concurrently With JANUVIA® (Sitagliptin) in Subjects With Type 2 Diabetes Mellitus

Resource links provided by NLM:

Further study details as provided by Lexicon Pharmaceuticals:

Primary Outcome Measures:
  • Change from baseline in gut hormones [ Time Frame: Days 1, 8, and 15 ]

Secondary Outcome Measures:
  • Change from baseline in fasting plasma glucose [ Time Frame: Days 1, 8, and 15 ]
  • Change from baseline in postprandial glucose [ Time Frame: Days 1, 8, and 15 ]
  • Change from baseline in insulin [ Time Frame: Days 1, 8, and 15 ]
  • Change from baseline in peptide YY [ Time Frame: Days 1, 8, and 15 ]
  • Change from baseline in urinary glucose excretion [ Time Frame: Days 1, 8, and 15 ]

Enrollment: 18
Study Start Date: October 2011
Primary Completion Date: November 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment A Drug: LX4211
400 mg of LX4211 administered as two 200 mg tablets
Experimental: Treatment C Drug: LX4211
400 mg of LX4211 administered as two 200 mg tablets
Drug: Januvia®
100 mg Januvia® (sitagliptin) administered as one 100 mg sitagliptin tablet
Active Comparator: Treatment B Drug: Januvia®
100 mg Januvia® (sitagliptin) administered as one 100 mg sitagliptin tablet


Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults aged 18 to 65 years of age
  • History of Type 2 Diabetes Mellitus for at least 3 months prior to Screening, with HgbA1c values of 6.5 to 10.5% and C-peptide ≥1.0 ng/mL
  • Body mass index (BMI) ≤45 kg/sq m
  • Willing and able to self-monitor blood glucose
  • Able to provide written informed consent

Exclusion Criteria:

  • History of Type 1 diabetes mellitus, diabetic ketoacidosis, hyperosmolar nonketotic syndrome, or diabetes resulting from pancreatic disorder or secondary diabetes
  • Current use of any blood glucose lowering agent other than metformin
  • History of renal disease or clinically significant abnormal kidney function tests at Screening or Day -2
  • Presence of active hepatic disease or clinically significant abnormal liver function tests at Screening or Day -2
  • History of myocardial infarction, severe/unstable angina, or coronary revascularization procedure within 6 months of Day -2
  • History of clinically significant cardiac arrhythmias within 1 year of Day -2
  • Congestive heart failure and/or New York Heart Association (NYHA) class III or IV symptoms of heart failure
  • Subjects with uncontrolled Stage 3 hypertension
  • History of 2 or more emergency room visits, doctor's visits, or hospitalizations due to hypoglycemia within 6 months of Day -2
  • History of alcohol or drug abuse within 12 months of Screening
  • History of bowel resection > 20 cm, any malabsorptive disorder, severe gastroparesis, and GI procedure for the purpose of weight loss that would slow gastric emptying
  • History of HIV or hepatitis C
  • Major surgery within 3 months of Day -2 or any planned surgery during the study
  • History of any active infection within 2 weeks of Day -2
  • History of pancreatitis
  • History of any malignancy within the last 5 years which would affect the diagnosis or assessment of LX4211 or sitagliptin
  • History of any serious adverse reaction or hypersensitivity to LX4211 or sitagliptin
  • Presence of any clinically significant physical, laboratory, or ECG findings or any concurrent condition at Screening that may interfere with the study in the opinion of the investigator
  • Triglycerides > 1000 mg/dL at Screening or Day -2
  • Donation or loss of >400 mL of blood or blood product within 8 weeks prior to Day -2
  • Use of any tobacco product for the duration of study participation
  • Use of corticosteroids within 2 weeks of Day 1
  • Use of digoxin or warfarin within 2 weeks prior to Screening
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01441232

United States, Texas
Lexicon Investigational Site
San Antonio, Texas, United States, 78209
Sponsors and Collaborators
Lexicon Pharmaceuticals
Study Director: Ikenna Ogbaa, MD Lexicon Pharmaceuticals, Inc.
  More Information

Publications automatically indexed to this study by Identifier (NCT Number):
Responsible Party: Lexicon Pharmaceuticals Identifier: NCT01441232     History of Changes
Other Study ID Numbers: LX4211.1-105-DM
LX4211.105 ( Other Identifier: Lexicon Pharmaceuticals, Inc. )
Study First Received: September 23, 2011
Last Updated: January 26, 2012

Additional relevant MeSH terms:
Diabetes Mellitus
Diabetes Mellitus, Type 2
Glucose Metabolism Disorders
Metabolic Diseases
Endocrine System Diseases
Sitagliptin Phosphate
Hypoglycemic Agents
Physiological Effects of Drugs
Hormones, Hormone Substitutes, and Hormone Antagonists
Dipeptidyl-Peptidase IV Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on May 25, 2017